GLP-1 receptor agonists work by maintaining pharmacological levels of a hormone that the body produces only transiently after meals. When the medication is withdrawn, the sustained appetite suppression ends and hunger returns, typically to levels above those experienced before treatment. This is not a failure of willpower. It is a predictable physiological response to the removal of a pharmacological agent that was suppressing appetite through a mechanism unrelated to lifestyle or psychology.
The STEP 4 and SURMOUNT-4 Trials on Drug Cessation
The STEP 4 trial, published in the Journal of the American Medical Association in 2021, examined what happened when adults who had achieved weight loss on semaglutide were switched to placebo. Over 48 weeks following cessation, participants regained an average of 7 percent of their body weight, recovering approximately two thirds of the weight they had lost during treatment. The SURMOUNT-4 trial of tirzepatide, published in JAMA in 2024, found similar results: participants who discontinued tirzepatide after achieving weight loss regained a significant proportion of lost weight within the observation period, while those who continued treatment maintained their weight loss.
These findings confirm that GLP-1 drugs function as ongoing treatments for a chronic condition rather than curative interventions. The biological mechanisms that drive excess weight accumulation in affected individuals do not resolve during treatment. They are suppressed by the medication and resume when it is withdrawn. This has significant implications for how the decision to start treatment is framed, and for what lifestyle infrastructure must be built during treatment to support maintenance after it ends.
What Happens to Muscle After Treatment Ends
Muscle lost during GLP-1 treatment does not return automatically when treatment stops. Skeletal muscle requires a specific anabolic stimulus to be rebuilt: progressive resistance training, adequate protein, and positive energy balance. Adults who stop GLP-1 treatment without an established resistance training practice and adequate protein intake face weight regain that is disproportionately fat rather than lean mass. Because their resting metabolic rate has been reduced by muscle loss and their insulin sensitivity has been reduced by the same mechanism, regained weight accumulates more easily and in a worse body composition ratio than the weight that was originally lost.
Building the Infrastructure That Outlasts the Medication
The evidence suggests that the most successful long-term outcomes from GLP-1 treatment occur when the pharmacological period is used to build lifestyle practices that can support weight maintenance without ongoing medication. These include establishing a consistent resistance training habit that preserves and rebuilds lean mass, developing dietary patterns based on whole food protein sources, vegetables, and minimally processed foods, and building an understanding of hunger, satiation, and caloric density that functions independently of appetite suppression.
A clinical health coach with expertise in body composition, nutrition, and resistance training has a specific role in GLP-1 treatment: to ensure that the period of pharmacological appetite suppression is used to embed the habits that make the medication eventually unnecessary, rather than to produce weight loss that reverses entirely when the drug is withdrawn.
- STEP 4 trial: patients stopping semaglutide regained approximately two thirds of lost weight within 48 weeks
- SURMOUNT-4 trial: similar pattern with tirzepatide; continued treatment maintained weight loss, discontinuation did not
- Weight regained after stopping is disproportionately fat rather than lean mass
- Muscle lost during treatment does not return without progressive resistance training and adequate protein
- GLP-1 drugs treat a chronic condition: the underlying mechanisms resume when medication stops
- The treatment period should be used to build dietary and exercise habits that support maintenance after cessation
- Resistance training three times weekly during treatment builds the metabolic infrastructure that outlasts the medication